Project Description

Author: Moniruzzaman et al.


Anti-VEGF therapies have emerged as the standard treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME), leading to a significant reduction in vision loss. However, the frequent injections required for these therapies impose a burden on patients, caregivers, and the healthcare system. Additionally, maintaining long-term visual improvement can be challenging. To address these issues, Brolucizumab, an intravitreal anti-VEGF therapy, has been approved for the treatment of AMD and DME. It offers a longer duration of action and a drying effect, potentially reducing the need for frequent injections and providing an effective treatment option. However, it can be challenging to strike a balance between the benefits and risks associated with Brolucizumab. Reports have indicated cases of intraocular inflammation (IOI) in patients receiving Brolucizumab, which, if left untreated, could lead to severe vision loss. Further data is required to better understand the efficacy of Brolucizumab, its swiftness in achieving complete fluid resolution, and its impact on visual outcomes. This case series aims to evaluate visual acuity, retinal thickness, macular volume, and adverse effects in patients with DME and AMD who are treated with Brolucizumab in Bangladesh. The goal is to gather valuable information that can contribute to the characterization of Brolucizumab’s effectiveness and safety in this particular patient population.

Status: Ongoing

Full-text link: Not available